Mazen Noureddin and Stephen Harrison discuss future directions cost-effectiveness research in and outside the U.S. might take, while the Surfers consider the implications.
In response to questions from Roger Green and Stephen Harrison, this conversation starts by exploring where cost-effectiveness research might head next. Louise Campbell provides context from other recent studies and Stephen asks about the impact of expanding these models to encompass costs of hepatocellular carcinoma. At the end of this conversation, the group considers how public explanation of expanded testing might sit with patients and other stakeholders.